Georgios Tsamboukas, Vasilios Vossos, K. Gkeka, I. Kotsikogianni, A. Papatsoris, Aristomenis Gkekas
{"title":"Paraganglioma of the urinary bladder","authors":"Georgios Tsamboukas, Vasilios Vossos, K. Gkeka, I. Kotsikogianni, A. Papatsoris, Aristomenis Gkekas","doi":"10.19264/HJ.V29I4.206","DOIUrl":"https://doi.org/10.19264/HJ.V29I4.206","url":null,"abstract":"Paragangliomas are rare tumors, of neuroendocrine origin. These neoplasms are equivalent to extra-adrenal pheochromocytomas and their symptoms attributed to the secretion of catecholamines. When the urinary system is affected, the urinary bladder is implicated in the majority of the cases with the most specific symptom to be the hypertensive crisis during urination. Paragangliomas are considered benign, although in a small proportion of cases they may demonstrate aggressive biologic behavior. No distinct factors exist which distinguish these two groups; therefore, the follow-up of the patients with this rare tumor has to be close and long-term.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"80 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127447306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Dellis, Dionysios Delaportas, K. Nastos, G. Polymeneas
{"title":"Female urogenital fistulas","authors":"A. Dellis, Dionysios Delaportas, K. Nastos, G. Polymeneas","doi":"10.19264/HJ.V29I4.210","DOIUrl":"https://doi.org/10.19264/HJ.V29I4.210","url":null,"abstract":"Urogenital fistulas represent a significant maternal morbidity from obstetric and urogynecologic causes. Although uncommon, they suggest a source of significant personal and social morbidity. Precise diagnostic evaluation is the cornerstone of successful treatment along with skillful surgeons. In most cases they can be managed transvaginally, however more complexed cases require transperitoneal procedures either open or minimally invasive. In the present study we review optimal diagnosis and treatment methods of most frequent urogenital fistulas.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114231376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of radical surgery in the treatment of lymph node positive prostate cancer","authors":"F. Kapogiannis, C. Fasoulakis","doi":"10.19264/HJ.V29I4.211","DOIUrl":"https://doi.org/10.19264/HJ.V29I4.211","url":null,"abstract":"There is no clear consensus on how to manage a subset of patients with prostate cancer (PCa) who present with involved lymph nodes (LN+). Although outcomes for these patients are uniformly worse than those for patients with localized PCa, they are better than outcomes for patients with bone metastases, with more than 60% of patients alive at 10 years after the initial diagnosis. Although radical prostatectomies in patients with clinical lymphadenopathy were abandoned in the era before widespread adoption of PSA screening, radical prostatectomy with extended pelvic lymphadenectomy can help achieve durable cancer control in the contemporary practise. The use of multimodal treatment, including surgery, adjuvant radiotherapy, and ADT, is particularly relevant for younger patients who are at high risk for local and distant relapse over the course of their lives and who may need all treatments to achieve optimal outcomes. Although there is a lack of data from prospective randomized trials directly comparing radiotherapy and radical prostatectomy, retrospective studies and registries suggest that surgery may offer benefits in terms of biochemical recurrence-free survival, metastasis-free survival, prostate-cancer-specific mortality, and overall survival.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"58 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115398706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Evangelos Boulinakis, K. Safioleas, E. Koutsokostas, I. Gerzelis
{"title":"Plasmacytoma of the testis in a patient with previous multiple myeloma. A rare case report and review of the literature.","authors":"Evangelos Boulinakis, K. Safioleas, E. Koutsokostas, I. Gerzelis","doi":"10.19264/hj.v29i3.176","DOIUrl":"https://doi.org/10.19264/hj.v29i3.176","url":null,"abstract":"Multiple myeloma is a plasma cell tumor that homes to and expands in the bone marrow and that, despite the new available drugs, remains incurable. We report the case of a 69-year-old male with multiply relapsed multiple myeloma(MM), who was found to have a testicular plasmacytoma. He presented with a gradually enlarging scrotal mass. Following orchidectomy, pathologic examination of the specimen demonstrated a plasmacytoma.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122185625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neurogenic bladder in Multiple Sclerosis","authors":"A. Dellis, I. Mitsogiannis, D. Mitsikostas","doi":"10.19264/HJ.V29I2.169","DOIUrl":"https://doi.org/10.19264/HJ.V29I2.169","url":null,"abstract":"Multiple sclerosis is the commonest progressive neurological disorder in young people, with lower urinary tract dysfunction suggesting a common and morbid component, affecting the vast majority of patients. Although urinary symptoms are very common, there are no prospective trials to date regarding management options for bladder dysfunction in multiple sclerosis patients. Additionally, it was only recently when well designed attempts regarding detailed evaluation and management came up, with validated questionnaires and new kinds of medication. In the present study we try to show up the urologic aspects of this progressive debilitating neurological disorder as well as we review current treatment strategies of neurogenic lower urinary tract dysfunction in multiple sclerosis patients.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121749196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Papadopoulos, C. Fragkoulis, I. Glykas, K. Tsirkas, K. Stasinopoulos, G. Stathouros, K. Ntoumas
{"title":"The effect of neoadjuvant chemotherapy on the perioperative morbidity of patients undergoing radical cystectomy for bladder cancer","authors":"G. Papadopoulos, C. Fragkoulis, I. Glykas, K. Tsirkas, K. Stasinopoulos, G. Stathouros, K. Ntoumas","doi":"10.19264/HJ.V29I3.171","DOIUrl":"https://doi.org/10.19264/HJ.V29I3.171","url":null,"abstract":"Introduction: Radical cystectomy (RC) with concurrent lymph node dissection is the treatment choice in muscle invasive bladder cancer (MIBC). The use of neoadjuvant chemotherapy (NAC) in patients with MIBC who will undergo RC appears to improve 5-year survival by 5% without affecting the perioperative morbidity of patients. The aim of this study is to present the effect of NAC on perioperative morbidity in patients undergoing RC in our department. Material and Methods: A retrospective study of the data of patients undergoing radical cystectomy for MIBC was performed in our department regarding the years 2016 and 2017. Patients were divided into two groups depending on whether they received NAC or not. Afterwards, a comparison of the perioperative morbidity between the 2 groups was performed as expressed by the duration of surgery, the time of hospitalization, the occurrence of complications and the need for immediate re-intervention. Results: Patients who underwent NAC were younger in a statistical significant way. On the other hand, there was no statistically significant difference between the two groups regarding the duration of surgery, the time of hospitalization, the need for reoperation, the appearance of wound infection, the occurrence of urinary tract infection, the need for transfusion, the appearance of deep vein thrombosis or the occurrence of complications from the cardiovascular and respiratory system.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124284529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Mourmouris, Christos Papachristou, Titos Markopoulos, M. Zerva, O. B. Argun, M. Tuna, A. Skolarikos
{"title":"Zero ischemia partial nephrectomy: Techniques and outcomes","authors":"P. Mourmouris, Christos Papachristou, Titos Markopoulos, M. Zerva, O. B. Argun, M. Tuna, A. Skolarikos","doi":"10.19264/HJ.V29I2.194","DOIUrl":"https://doi.org/10.19264/HJ.V29I2.194","url":null,"abstract":"Νephron sparing techniques nowadays have replaced radical nephrectomy as the gold standard management for T1a tumors. Even though the basic step of this technique was hilar clamping in order to achieve a bloodless surgical field and ease tumor excision and rennoraphy, many surgeons have moved one step further and developed minimal or no vessel clamping. These techniques were grouped under the title of zero ischemia partial nephrectomy. Nevertheless there is a great heterogeneity in the literature concerning every aspect of this term including surgical steps, oncological outcomes and functional results. The purpose of this paper is to review the literature about this interesting topic and to clarify the different aspects of this challenging procedure.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"379 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124725468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Chondros, J. Ménard, P. Bryckaert, É. Mandron, N. Hoarau
{"title":"From candlelight to digital imaging cystoscopy: A comprehensive review of bladder’s endoscopy evolution","authors":"K. Chondros, J. Ménard, P. Bryckaert, É. Mandron, N. Hoarau","doi":"10.19264/hj.v29i2.167","DOIUrl":"https://doi.org/10.19264/hj.v29i2.167","url":null,"abstract":"The birth of modern cystoscopy begun two centuries ago after the initial invention of Bozzini’s prototype urethroscope that used candlelight. Since then cystoscopy has been submitted to several improvements ranging from practical instrumentation modifications to advanced light source systems and enhanced image quality. Visualization melioration of the bladder used technological innovations, such as fiber-optics, and led to flexible endoscopes with digital imaging. The last two decades, systems with image enhancement capabilities have emerged in an effort to improve endoscopic vision and detection of bladder pathological lesions. The present review includes the main hallmarks of the historic evolution of today’s cystoscopes, the current endoscopic systems and the future trends in bladder’s visualization.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"16 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126130952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is there any potential role for the elastography on the evaluation of clinical success of prostate artery embolization (PAE) on the treatment of benign prostatic hyperplasia (BPH)","authors":"K. Stamatiou","doi":"10.19264/hj.v29i3.198","DOIUrl":"https://doi.org/10.19264/hj.v29i3.198","url":null,"abstract":"Benign prostatic hyperplasia (BPH) is a very common condition in the male. It typically occurs in the sixth and seventh decades. Actually BPH is a histologic finding that becomes a clinical entity if and when it is associated with subjective symptoms. Not all men with histologic BPH will have significant lower urinary tract symptoms (LUTS) and other men who do not have histologic BPH will develop. In fact LUTS are also present in other diseases such as infection and cancer of the prostate, urethral stricture, etc. Traditionally, symptomatic benign prostatic hyperplasia is treated with either medical therapy or surgery. Among prostate-directed treatment modalities, prostate artery embolization (PAE) is the less invasive non pharmaceutical treatment. Initial studies showed that PAE led to reduction of the prostatic volume, symptom remission and improvements in quality of life. As a relatively new procedure, few data exist to clearly determine the exact mechanism(s) by which PAE achieve the above results.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123538935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The role of emerging therapies in the treatment of benign prostatic hyperplasia. Is it any place","authors":"I. Glykas, I. Gkialas","doi":"10.19264/hj.v29i3.197","DOIUrl":"https://doi.org/10.19264/hj.v29i3.197","url":null,"abstract":"Benign prostatic hyperplasia (BPH) may lead to bladder outflow obstruction and symptoms in older men The latest developments as far as it concerns surgical treatment are focused on two principles: an office based procedure without the need for general anesthesia; and minimizing incontinence and sexual dysfunction related side effects while retaining satisfactory clinical efficacy. The aim of this review is to evaluate evolving minimally invasive therapies for the treatment of lower urinary tract symptoms (LUTS) caused by BPH in which ongoing clinical trials show early promise, namely, intra-prostatic injections, alcohol ablation, aquablation, the Rezum device, prostatic artery embolization (PAE), and histotripsy.","PeriodicalId":185530,"journal":{"name":"Hellenic Urology","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124652895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}